Detalhe da pesquisa
1.
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Nat Chem Biol
; 11(6): 432-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915199
2.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell
; 36(1): 100-114.e25, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257072
3.
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
Mol Cancer Ther
; 16(5): 850-860, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28292935
4.
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Mol Cancer Ther
; 16(11): 2586-2597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835384
5.
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.
Sci Rep
; 7(1): 17993, 2017 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29269946
6.
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.
ACS Med Chem Lett
; 6(6): 655-9, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26101569
7.
Promoter choice determines splice site selection in protocadherin alpha and gamma pre-mRNA splicing.
Mol Cell
; 10(1): 21-33, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12150904